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after thrombolysis with tissue plasminogen activator
Zoltán Szeberin, MD, PhD, Gábor Viktor Szabó, MD, PhD, Péter Sótonyi, MD, PhD, and
Edit Dósa, MD, PhD, Budapest, HungaryA 56-year-old man was admitted to our department with acute critical left
leg ischemia. He had undergone multiple arterial reconstructions of the
affected leg over the past 2 years. The last reconstruction was a femorotibial
composite silver-impregnated Dacron autologous saphenous vein bypass.
Digital subtraction angiography (DSA) showed occlusion of the graft;
therefore, selective transcatheter thrombolysis with tissue plasminogen
activator ([tPA] alteplase) was started. The 10-mg bolus dose was followed
by continuous infusion at a rate of 2.0 mg/h. In addition, heparin was
administered intravenously, starting at 500 IU/h and adjusted according
to activated clotting time. DSA performed 8 hours later demonstrated
almost complete resolution of the thrombus but revealed a signiﬁcant
stenosis at the graft-vein anastomosis. The silver-impregnated graft was
leaking diffusely (A), but the bleeding was conﬁned to the perigraft ﬁbrous
capsule (B). Considering the possible risk of major bleeding or graft failure
at balloon angioplasty/stenting, open surgical graft revision was per-
formed. The stenotic segment was replaced with a short Dacron interposi-
tion. The patient was discharged 5 days later with palpable peripheral
pulses.
Intra-arterial thrombolysis with tPA or urokinase is a nonsurgical
treatment option for acute critical lower-extremity ischemia caused by
graft occlusion.1 Although starting thrombolysis 10 to 14 days after
surgery is generally accepted to be safe, no exact treatment guidelines
concerning dosage, timing, route, and duration of tPA administration
are available.2,3
In our case, a silver collagen-coated polyester graft had been implanted
8 months earlier. No signs of perigraft infection were present, and the graft
was well incorporated into the surrounding tissues. However, control DSA
demonstrated diffuse leakage through the whole prosthesis. This phenom-
enon has not yet been observed in our practice (>100 patients) with tPA
thrombolysis. In this case, thrombolysis and reconstruction of the culprit
stenosis saved the patient’s leg, but care should be taken when performing thrombolysis of grafts implanted 8 months
ago because of the possibility of leakage. Absence of perigraft ﬁbrotic capsule in the case of ongoing infection may lead
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